// App-Quantinova.ai

855 : p53 isoform A133p53a triple negative breast cancer and increased relapse with neoadjuvant taxanes

Researchers

Presenter

  • Jean-Christophe Bourdon

Principal Investigators

  • Alexandra Diot

  • Valerie Meuray

  • Leen Slaets

  • Richard Iggo

  • Herve Bonnefoi

  • David Cameron

  • Alastair M. Thompson

Medical Centers

  • Dundee Cancer Centre, Dundee, United Kingdom

  • EORTC HQ, Brussels, Belgium

  • Institut Bergonie, Bordeaux, France

  • Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • France

  • United States

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • p53

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

  • Tumor protein p53

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Fluorouracil

  • Adrucil injection

  • Epirubicin

  • Docetaxel

  • taxane

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved